8-K: Aptose Secures $11.9M Loan for AML Drug Development

Aptose Biosciences extended its loan agreement with Hanmi Pharmaceutical for $11.9 million to advance its AML drug tuspetinib, citing positive clinical data.

Summary

• Aptose Biosciences Inc. entered into a US$11.9 million Amended Facility Agreement with Hanmi Pharmaceutical Co. Ltd. on September 22, 2025.
• The loan is uncommitted, administered through multiple advances until December 31, 2025, and will fund business and clinical operations for tuspetinib.
• No single advance will exceed US$2,000,000, and any unpaid principal accrues interest at 6% per annum.
• Aptose has not yet received funds from this new agreement but expects the first advance soon.
• The company also received the final US$1.4 million advance from a prior June 2025 Facility Agreement, bringing the total from that prior agreement to US$8.5 million.
• Tuspetinib (TUS) is being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML) patients ineligible for induction chemotherapy.
• Early data from the TUSCANY triplet Phase 1/2 study demonstrated safety, complete remissions (CRs), and minimal residual disease (MRD) negativity across diverse mutations.
• 9 out of 10 patients responded to the TUS triplet therapy, with 100% complete remission (CR/CRh) achieved in the 80mg and 120mg cohorts.
• Patients with difficult-to-treat mutations in TP53, RAS, and FLT3 genes also achieved a 100% CR/CRh rate.

Sentiment

Score: 8

Explanation: The securing of significant funding, coupled with very strong early clinical data for tuspetinib, indicates a highly positive development for the company's lead asset. The related-party nature and 'uncommitted' aspect of the loan introduce minor caveats, but the overall news is favorable for continued development and potential future success.

Positives

• Secured US$11.9 million in additional funding to continue the development of tuspetinib.
• Positive early clinical data for tuspetinib in AML, demonstrating safety and efficacy.
• High response rates (9 out of 10 patients) and 100% complete remission (CR/CRh) in the 80mg and 120mg cohorts.
• Tuspetinib showed efficacy in difficult-to-treat AML patient populations with TP53, RAS, and FLT3 mutations.
• Tuspetinib is a convenient once-daily oral agent with a favorable toxicity profile, avoiding typical concerns observed with other agents.
• Continued support from Hanmi Pharmaceutical, a key partner in the development of tuspetinib.

Negatives

• The US$11.9 million loan facility is 'uncommitted,' implying that future advances are not guaranteed.
• Aptose has not yet received funds from the new Amended Facility Agreement, indicating that immediate cash flow from this specific agreement is pending.
• The company is relying on a financial hardship exemption for the related-party transaction with Hanmi, which may suggest underlying liquidity or financial position challenges.
• The 6% annual interest rate on unpaid principal represents a cost of capital for the company.

Risks

• The ability to negotiate a collaboration agreement to jointly develop tuspetinib with Hanmi is not assured.
• The company's ability to remain compliant with TSX listing requirements is an ongoing risk.
• Forward-looking statements are subject to significant business, economic, competitive, political, and social uncertainties and contingencies.
• Actual results may vary materially from forward-looking statements due to various factors detailed in ongoing quarterly and annual filings.
• The 'uncommitted' nature of the loan facility means that future advances are not guaranteed, posing a funding risk.
• Reliance on the financial hardship exemption for the related-party transaction could indicate financial vulnerability.

Future Outlook

Aptose Biosciences expects to continue the development of tuspetinib as a frontline triplet therapy for AML, aiming to safely and effectively treat a broad patient population, including those with adverse genetics. The company anticipates receiving the first advance from the US$11.9 million loan agreement soon.

Management Comments

• "The growing body of positive data on tuspetinib demonstrates that, by adding TUS to the VEN+AZA standard of care in AML, we can safely and more effectively treat some of AMLs largest patient populations, in addition to subgroups having adverse genetics defined by FLT3, NKRAS, and TP53 genes."
• "We are very grateful for Hanmis support for the continued development of an important new treatment in the AML armamentarium."

Industry Context

The development of novel, targeted therapies like tuspetinib for AML is a critical area in oncology, especially for patients ineligible for standard induction chemotherapy or those with difficult-to-treat mutations. The focus on triplet therapy combining a new agent with established standards (venetoclax and azacitidine) reflects a broader industry trend towards combination regimens to improve efficacy and overcome resistance in hematological malignancies.

Comparison to Industry Standards

• The 100% CR/CRh rate in the 80mg and 120mg cohorts, particularly in patients with challenging TP53, RAS, and FLT3 mutations, represents a strong early indicator compared to historical response rates for these difficult-to-treat AML subgroups.
• Tuspetinib's mechanism targeting multiple kinases (SYK, FLT3, KIT, JAK1/2, RSK2) while avoiding typical toxicities positions it favorably against single-target agents or those with broader, less specific kinase inhibition profiles.
• The use of a triplet therapy (TUS+VEN+AZA) aligns with emerging standards in AML, where combinations are increasingly preferred over monotherapy to achieve deeper and more durable responses, especially in patients unfit for intensive chemotherapy.

Corporate Governance

Related Party Transactions

• The US$11.9 million Amended Facility Agreement with Hanmi Pharmaceutical Co. Ltd. constitutes a related-party transaction under Canadian securities laws (Multilateral Instrument 61-101).
• Hanmi Pharmaceutical is considered a related party of Aptose Biosciences Inc.
• Aptose is relying on the financial hardship exemption from formal valuation and minority shareholder approval requirements under MI 61-101.

Stakeholder Impact

• Shareholders: Potential positive impact due to secured funding for drug development and promising clinical data, which could increase the company's valuation and future prospects. However, the loan incurs interest and the 'uncommitted' nature adds some uncertainty.
• Patients (AML): Highly positive impact as the continued development of tuspetinib offers a potential new, effective, and safer treatment option, especially for those with difficult-to-treat mutations or who are ineligible for standard chemotherapy.
• Employees: Continued employment and stability due to funding for ongoing operations and clinical programs.
• Hanmi Pharmaceutical: Strengthened partnership and potential future returns from their investment in Aptose and tuspetinib.

Next Steps

• Receive the first advance from the US$11.9 million Amended Facility Agreement.
• Continue the TUSCANY triplet Phase 1/2 study for tuspetinib in newly diagnosed AML patients.
• Further develop tuspetinib as a frontline triplet therapy for AML.

Key Dates

Recommendation

The filing details a significant funding injection of US$11.9 million, crucial for advancing the company's lead oncology asset, tuspetinib. More importantly, the clinical data presented for tuspetinib in AML is exceptionally strong, showing 100% complete remission rates in key cohorts and efficacy in difficult-to-treat patient populations. This combination of secured financing and highly promising clinical results significantly de-risks the development pathway and enhances the drug's commercial potential, making it a compelling investment opportunity.

Keywords

Aptose Biosciences, Hanmi Pharmaceutical, Tuspetinib, AML, Acute Myeloid Leukemia, Oncology, Clinical Trial, Phase 1/2, TUSCANY study, Kinase Inhibitor, FLT3, SYK, TP53, RAS, Venetoclax, Azacitidine, Loan Agreement, Biotechnology, Precision Medicine